Cargando…

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated with these drug-related adverse events are poorly characterized. Our objective was to investigate such factors in patients treated long term with daily tenofovir. One-hundred Caucasian HIV-posi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gervasoni, Cristina, Meraviglia, Paola, Landonio, Simona, Baldelli, Sara, Fucile, Serena, Castagnoli, Laura, Clementi, Emilio, Riva, Agostino, Galli, Massimo, Rizzardini, Giuliano, Cattaneo, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846565/ https://www.ncbi.nlm.nih.gov/pubmed/24312465 http://dx.doi.org/10.1371/journal.pone.0080242

Ejemplares similares

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Does lopinavir really inhibit SARS-CoV-2?
por: Cattaneo, Dario, et al.
Publicado: (2020)

Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers
por: Cossu, Maria Vittoria, et al.
Publicado: (2014)

Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study
por: Capetti, Amedeo Ferdinando, et al.
Publicado: (2017)

Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients()
por: Charbe, Nitin, et al.
Publicado: (2016)

Management of Polypharmacy and Potential Drug–Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic
por: Cattaneo, Dario, et al.
Publicado: (2023)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Management of diabetes mellitus in people living with HIV: A single-center experience
por: Cattaneo, Dario, et al.
Publicado: (2023)

Clinical and genetic determinants of nevirapine plasma trough concentration
por: Giacomelli, Andrea, et al.
Publicado: (2018)

Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy
por: Giacomelli, Andrea, et al.
Publicado: (2018)

Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate?
por: Giacomelli, Andrea, et al.
Publicado: (2021)

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
por: Landonio, S, et al.
Publicado: (2010)

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
por: Capetti, Amedeo, et al.
Publicado: (2012)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

Inflammation and neurological adverse drugs reactions: a case of long lasting impaired consciousness after oxatomide administration in a patient with gastroenteritis
por: Antoniazzi, Stefania, et al.
Publicado: (2012)

Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure
por: Corti, Silvia, et al.
Publicado: (2019)

Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects
por: Carnovale, Carla, et al.
Publicado: (2022)

Darunavir does not prevent SARS-CoV-2 infection in HIV patients
por: Riva, Agostino, et al.
Publicado: (2020)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group
por: Ferretti, Francesca, et al.
Publicado: (2021)

Hepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?
por: Chiesa, Annacarla, et al.
Publicado: (2020)

Trends in hospital admissions at a Department for Infectious Diseases in Italy from 1995 to 2011 and implications for health policies
por: Orlando, Giovanna, et al.
Publicado: (2014)

Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
por: Cattaneo, Dario, et al.
Publicado: (2020)

The Issue of Pharmacokinetic-Driven Drug-Drug Interactions of Antibiotics: A Narrative Review
por: Cattaneo, Dario, et al.
Publicado: (2022)

Comorbidities and HCV coinfection in the management of HIV+ patients: evidence from the Italian clinical practice
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine
por: Pogliani, Laura, et al.
Publicado: (2012)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir
por: Francisci, D, et al.
Publicado: (2010)

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
por: Capetti, Amedeo F., et al.
Publicado: (2021)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
por: Restelli, Umberto, et al.
Publicado: (2014)

Ganciclovir–tenofovir interaction leading to tenofovir-induced nephrotoxicity
por: Soanker, Radhika, et al.
Publicado: (2014)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)

Sex Hormones Regulate Tenofovir-Diphosphate in Female Reproductive Tract Cells in Culture
por: Shen, Zheng, et al.
Publicado: (2014)

Multidrug-resistant HIV viral rebound during early syphilis: a case report
por: Giacomelli, Andrea, et al.
Publicado: (2020)

Comment on “Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6”
por: Cattaneo, Dario, et al.
Publicado: (2021)

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
por: Kumar, Princy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_42oucfoc82f157boian0rqvff7